Did Rebel Wilson confirm using Ozempic specifically?

Yes. Wilson has publicly confirmed using Ozempic as part of her weight management approach. She has not disclosed specific doses, duration, or her prescribing clinician's identity.

How much weight did Rebel Wilson lose?

Wilson has discussed losing approximately 35 kg (77 lb) during and after her 2020 "Year of Health." She attributed the loss to a combination of lifestyle changes and, later, Ozempic use.

Why did Rebel Wilson regain weight after stopping Ozempic?

Post-discontinuation weight regain is a well-documented pharmacological outcome, not a personal failure. The STEP 1 extension trial showed that patients regain roughly two-thirds of lost weight within one year of stopping semaglutide. The drug suppresses appetite through central nervous system pathways; removing it allows appetite to return to pre-treatment levels.

Is Ozempic approved for weight loss?

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved for type 2 diabetes. It is frequently prescribed off-label for weight management. Wegovy (semaglutide 2.4 mg) is the formulation specifically approved for chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity.

How long do you need to take semaglutide to keep the weight off?

Current evidence and Endocrine Society guidelines support indefinite use for patients who respond to treatment and tolerate the medication. There is no established protocol for a fixed-duration "course" of semaglutide for weight management. Stopping the drug reliably leads to weight regain in most patients.

What Rebel Wilson's Reported Protocol Might Look Like Clinically

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for What Rebel Wilson's Reported Protocol Might Look Like Clinically Image: HealthRX.com clinical image

At a glance

Status: Rebel Wilson has publicly confirmed Ozempic (semaglutide 0.5 mg/1 mg, later formulations up to 2 mg) use as part of her weight management.
Timeline: Wilson declared 2020 her "Year of Health," attributing initial results to diet, exercise, and mindset shifts. She later confirmed GLP-1 medication use.
Weight regain: Wilson has spoken openly about regaining weight after discontinuing the medication, consistent with published clinical trial extension data.
Drug: Ozempic (semaglutide), a once-weekly injectable GLP-1 receptor agonist originally approved for type 2 diabetes, widely prescribed off-label for weight management at the time of Wilson's reported use.

The public record: what Rebel Wilson has actually said

Wilson's weight loss journey became one of the most-discussed celebrity health stories of the early 2020s. She initially framed her roughly 35 kg (77 lb) loss as the product of a high-protein, low-carbohydrate dietary approach combined with daily walking and emotional eating work with a team of professionals. She discussed these changes extensively in interviews and in her 2023 memoir, Rebel Rising.

The Ozempic confirmation came later. Wilson acknowledged using the medication in public interviews, clarifying that the drug was part of her toolkit but not the sole driver. She did not disclose specific dosing, duration, or prescribing details.

What makes Wilson's story clinically relevant is what happened next. She has discussed publicly that she regained a portion of the weight after stopping the medication. That outcome is not a personal failing. It is a pharmacologically predictable result.

How semaglutide works: the mechanism in brief

Semaglutide is a modified human GLP-1 analogue with a 165-hour half-life, engineered for once-weekly subcutaneous injection. It acts on GLP-1 receptors in the pancreas (enhancing glucose-dependent insulin secretion), the gut (slowing gastric emptying), and the hypothalamus (reducing appetite signaling). The net effect: patients eat less because they feel full sooner and stay full longer.

The FDA approved Ozempic (semaglutide injection) for type 2 diabetes in 2017. A higher-dose formulation, Wegovy (semaglutide 2.4 mg), received FDA approval for chronic weight management in June 2021. Many patients, including those in Wilson's reported timeframe, used the Ozempic formulation off-label for weight loss before Wegovy's availability.

What a standard semaglutide protocol looks like

For a patient with Wilson's publicly described profile (BMI in the obese range at baseline, no publicly disclosed type 2 diabetes), a clinician following FDA prescribing guidelines would typically structure semaglutide dosing as follows:

Dose escalation schedule (Ozempic):

| Week | Dose | Purpose | |------|------|---------| | 1-4 | 0.25 mg weekly | GI acclimatization only; not a therapeutic dose | | 5-8 | 0.5 mg weekly | First therapeutic dose; appetite reduction begins | | 9+ | 1.0 mg weekly | Standard maintenance dose for most patients | | 9+ (if needed) | 2.0 mg weekly | Available since March 2022 for additional glycemic benefit |

The slow ramp matters. Semaglutide's most common side effects (nausea, vomiting, diarrhea, constipation) are dose-dependent and GI-mediated. Jumping straight to 1.0 mg produces dropout rates that undermine treatment. A 2021 NEJM trial (STEP 1) escalated patients over 16 weeks to 2.4 mg, with 4-week holds at each dose step.

For Wegovy (the weight-management formulation), the escalation reaches 2.4 mg over approximately 16 to 20 weeks: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg as maintenance.

The HealthRX.com Medical Team notes: Wilson's public timeline suggests she used Ozempic rather than Wegovy, likely at the 0.5 mg or 1.0 mg dose range. Without her clinical records (which are private and should remain so), this is an informed estimate based on what was available and commonly prescribed during the period she has described.

Expected weight loss: what the trials show

The STEP 1 trial enrolled 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) and randomized them to semaglutide 2.4 mg or placebo, both alongside lifestyle intervention. At 68 weeks:

Semaglutide group: mean weight loss of 14.9% of body weight
Placebo group: 2.4%
86.4% of the semaglutide group lost ≥5% body weight
69.1% lost ≥10%
50.5% lost ≥15%

At the lower Ozempic doses (0.5 mg, 1.0 mg), the SUSTAIN trials in type 2 diabetes patients showed weight reductions of approximately 3.5 to 6.4 kg over 30 to 56 weeks. Weight loss at these doses is real but more modest than at 2.4 mg.

Wilson's reported loss of approximately 35 kg is at the higher end of published trial outcomes. If she used Ozempic at 1.0 mg (the maximum standard Ozempic dose for much of her reported treatment window), the drug likely contributed a significant fraction of the total loss, with lifestyle modification accounting for an additional portion. The combination of pharmacotherapy and behavioral change consistently outperforms either approach alone.

The discontinuation problem: why weight comes back

This is the part of Wilson's story that carries the most clinical weight.

The STEP 1 trial extension study, published in Diabetes, Obesity and Metabolism in 2022, followed participants for one year after stopping semaglutide. The findings were stark:

Participants regained approximately two-thirds of their prior weight loss within 52 weeks of discontinuation
Cardiometabolic improvements (waist circumference, blood pressure, HbA1c, lipid levels) also reversed proportionally
The weight trajectory after stopping was not a gradual drift but a rapid initial regain followed by a plateau at a new, higher set point

This is not a willpower problem. GLP-1 receptor agonists suppress appetite through central nervous system signaling. When you remove the drug, the signaling reverts. Hunger returns to baseline. The body's energy-balance thermostat resets. A 2023 Lancet review described obesity as a chronic, relapsing condition requiring ongoing treatment, comparable to hypertension or hyperlipidemia: you would not expect blood pressure to remain controlled after stopping an antihypertensive.

The HealthRX.com Medical Team take: Wilson's publicly discussed weight regain is not an anecdote. It is a data point that matches what 1,961 clinical trial participants showed us. The STEP 1 extension data should be part of every informed consent conversation before starting semaglutide. Patients deserve to know that discontinuation will, in most cases, lead to substantial regain.

What a maintenance protocol would look like

For a patient who responds well to semaglutide and wants to maintain results, current evidence supports indefinite continuation at the tolerated maintenance dose. This is the clinical reality that many patients (and many prescribers) are still adjusting to.

A maintenance protocol based on published data and Endocrine Society guidelines would include:

Continued weekly injection at the effective dose (whether 1.0 mg Ozempic or 2.4 mg Wegovy)
Quarterly metabolic monitoring: fasting glucose, HbA1c, lipid panel, hepatic function
Annual thyroid assessment: semaglutide carries a boxed warning for medullary thyroid carcinoma risk based on rodent studies (not confirmed in humans, but monitoring is standard)
Concurrent lifestyle intervention: the drug is not a replacement for dietary quality and physical activity, which independently improve body composition and cardiometabolic health
Dose re-evaluation: some patients can step down to a lower maintenance dose (e.g., from 2.4 mg to 1.7 mg Wegovy) without full regain, though data on this approach is still maturing

The cost barrier is significant. Without insurance coverage, Ozempic runs approximately $900 to $1,100 per month. Wegovy is priced similarly. For many patients, the financial calculus, not the clinical calculus, drives the decision to stop.

Side effects Wilson's prescriber would have monitored

Based on STEP 1 safety data and the Ozempic prescribing information:

GI effects (nausea in 44% of trial participants, diarrhea in 30%, vomiting in 25%): most common in the first 8 to 12 weeks, usually mild to moderate, and typically self-limiting with dose escalation
Gallbladder events: cholelithiasis occurred in 2.6% of semaglutide patients vs. 1.2% on placebo. Rapid weight loss itself raises gallstone risk independent of the drug
Pancreatitis: rare (<0.2%) but requires vigilance. Any severe, persistent abdominal pain warrants immediate evaluation
Injection site reactions: mild erythema or pruritus in roughly 3.2% of patients
Hypoglycemia: uncommon as monotherapy in non-diabetic patients, but relevant if combined with sulfonylureas or insulin

Wilson has not publicly described experiencing specific side effects. The HealthRX.com Medical Team does not speculate on her private medical experience.

What Wilson's story tells us about GLP-1 prescribing

Three clinical takeaways emerge from Wilson's public journey:

First, lifestyle and pharmacotherapy are not competing strategies. Wilson spent a full year building exercise habits, addressing emotional eating, and restructuring her diet before adding a GLP-1 agonist. That sequencing may have contributed to a larger total effect. The STEP trials required lifestyle intervention in both arms, and the combination reliably outperforms either alone.

Second, stopping semaglutide is a medical decision, not a graduation. The language around "getting off" a weight-loss drug implies that the drug is a temporary scaffold. The biology says otherwise. For patients with obesity, GLP-1 agonists function more like chronic disease management than a course of antibiotics. Wilson's experience illustrates what the extension data confirmed at the population level.

Third, public disclosure shapes prescribing conversations. Wilson's openness about both the drug and the regain has given clinicians a concrete, high-visibility example when counseling patients about realistic expectations. That kind of public health communication has measurable value.

Frequently asked questions

›